Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Mirum Pharmaceuticals and keeping the price target at $81.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Ulz has given his Buy rating due to a combination of factors that highlight Mirum Pharmaceuticals’ strategic positioning and future prospects. Despite the recent filing by Sandoz for a generic version of Livmarli, Mirum’s management anticipated such a move and is prepared to defend its patents through a lawsuit, which will delay the approval of the generic drug for 30 months. This demonstrates Mirum’s proactive approach and confidence in its intellectual property portfolio.
Furthermore, the company is looking forward to the results of the Phase 2b trial for volixibat in the second quarter of 2026, which are expected to be positive. These developments, coupled with Mirum’s robust market capitalization and strategic planning, contribute to the positive outlook and justify the Buy rating. The company’s preparedness and strong defense against generic competition, along with promising pipeline developments, position it well for future growth.
According to TipRanks, Ulz is a 3-star analyst with an average return of 2.6% and a 43.71% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Kyverna Therapeutics, Inc., and Alnylam Pharma.
In another report released on November 12, TD Cowen also maintained a Buy rating on the stock with a $95.00 price target.